Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Abstract Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury. Our objectives were to report the frequency of cardiovascular (CV) events in patients treated with venetoc...
| Egile Nagusiak: | , , , , , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
BMC
2024-11-01
|
| Saila: | Cardio-Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s40959-024-00275-5 |